

News Releases

All Years

Search

Go

[Advanced Search](#)

AUG 18, 2020

Inhibrx Announces Pricing of Initial Public Offering of Common Stock

JAN 8, 2020

Inhibrx Announces Dosing of First Patient in Phase 1 Dose-Escalation Study of INBRX-106, a Novel Hexavalent Agonist of OX40

SEP 4, 2019

Inhibrx Announces Enrollment of First Patient in Phase 1 Study of INBRX-101, a Modified Recombinant Human AAT-Fc Fusion Protein

SEP 3, 2019

Inhibrx Reports Phase 1 Dose Escalation Results of INBRX-109, a Multivalent Agonist of Death Receptor 5

MAY 30, 2019

Inhibrx Announces Option Agreement for Development and Commercialization of INBRX-101 (AAT-Fc) Outside of the United States and Canada with Chiesi Group

Show 5  per page

[«](#) [1](#) [...](#) [6](#) [7](#) [8](#) [9](#) [10](#) [11](#) [12](#) [13](#) [14](#) [»](#)



<https://inhibrx.investorroom.com/news-releases?o=55>